Advertisement
UK markets closed

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • CRUDE OIL

    78.50
    +0.02 (+0.03%)
     

  • GOLD FUTURES

    2,323.60
    -7.60 (-0.33%)
     

  • DOW

    38,884.26
    +31.99 (+0.08%)
     

  • Bitcoin GBP

    50,473.55
    +1.18 (+0.00%)
     

  • CMC Crypto 200

    1,307.88
    -57.25 (-4.19%)
     

  • NASDAQ Composite

    16,332.56
    -16.69 (-0.10%)
     

  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

PTC Therapeutics (PTCT) reported $210.12 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 4.7%. EPS of -$1.20 for the same period compares to -$1.88 a year ago.

The reported revenue represents a surprise of +31.10% over the Zacks Consensus Estimate of $160.27 million. With the consensus EPS estimate being -$1.21, the EPS surprise was +0.83%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how PTC Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Net product revenue: $177.60 million versus $115.73 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.3% change.

  • Revenues- Royalty revenue: $31.15 million versus the five-analyst average estimate of $39.73 million. The reported number represents a year-over-year change of +1.1%.

  • Revenues- Net product revenue- Translarna: $103.60 million versus the four-analyst average estimate of $47.69 million. The reported number represents a year-over-year change of -10%.

  • Revenues- Net product revenue- Emflaza: $57.50 million versus the four-analyst average estimate of $52.06 million. The reported number represents a year-over-year change of +5.3%.

View all Key Company Metrics for PTC Therapeutics here>>>

Shares of PTC Therapeutics have returned -14.4% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

PTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research